4:09 PM ET
10-Q
Financial Results
Werewolf Therapeutics Q3 2026 Results: Net Loss of $9.88M, Loss Narrows
Werewolf Therapeutics is currently pursuing a merger with Ambros and a concurrent PIPE financing to address substantial doubt about its ability to continue as a going concern. As of November 9, 2026, the company had 48,599,066 shares of common stock outstanding and is evaluating strategies to raise additional capital to fund its research and development programs.
- Key figure
- Net loss $9.88M